CTSO - Cytosorbents outlines DrugSorb ATR regulatory appeals and targets core business breakeven as German reorganization drives 22% sales growth
2025-08-08 13:23:38 ET
More on Cytosorbents
- Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript
- Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript
- Cytosorbents outlines plans for DrugSorb-ATR appeal and targets breakeven core business by second half 2025
- Cytosorbents Non-GAAP EPS of -$0.06, revenue of $8.73M misses by $0.28M
- Seeking Alpha’s Quant Rating on Cytosorbents